Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans

Psychoneuroendocrinology

Volumn 46, Issue , 2014, Pages 23-31

  Kirkpatrick, Matthew G ^a   Francis, Sunday M ^b   Lee, Royce ^a   De Wit, Harriet ^a   Jacob, Suma ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Humans; MDMA; Mood; Oxytocin; Pharmacokinetics; Plasma

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; OXYTOCIN; PLACEBO; SEROTONIN RECEPTOR AFFECTING AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; EUPHORIA; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OXYTOCIN BLOOD LEVEL; PRIORITY JOURNAL; SOCIAL ASPECT; SUBJECTIVE EFFECT; ADOLESCENT; AFFECT; BLOOD; DRUG EFFECTS; HEMODYNAMICS; INTRANASAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SOCIAL BEHAVIOR; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AFFECT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMODYNAMICS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXYTOCIN; SEROTONIN AGENTS; SOCIAL BEHAVIOR; YOUNG ADULT;

EID: 84901441784     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.04.006     Document Type: Article

References (49)

1. Abraham T.T., Barnes A.J., Lowe R.H., Kolbrich Spargo E.A., Milman G., Pirnay S.O., et al. Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. J. Anal. Toxicol. 2009, 33:439-446.
2. Bedi G., Hyman D., de Wit H. Is ecstasy an empathogen? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol. Psychiatry 2010, 68:1134-1140.
3. Bedi G., Phan K.L., Angstadt M., de Wit H. Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl.) 2009, 207:73-83.
4. Born J., Lange T., Kern W., McGregor G.P., Bickel U., Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 2002, 5:514-516.
5. Bos P.A., Panksepp J., Bluthe R.M., Honk J.V. Acute effects of steroid hormones and neuropeptides on human social-emotional behavior: a review of single administration studies. Front. Neuroendocrinol. 2012, 33:17-35.
6. Bravo G.L. What does MDMA feel like?. Ecstasy: The Complete Guide. A Comprehensive Look at the Risks and Benefits of MDMA 2001, Park Street Press, Rochester, US. J. Holland (Ed.).
7. Carter C.S., Pournajafi-Nazarloo P., Kramer K.M., Ziegler T.E., White-Traut R., Bello D., Schwertz D. Behavioral associations and potential as a salivary biomarker. Ann. N. Y. Acad. Sci. 2007, 1098:312-322.
8. Di Simplicio M., Massey-Chase R., Cowen P.J., Harmer C.J. Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers. J. Psychopharmacol. 2009, 23:241-248.
9. Domes G., Heinrichs M., Glascher J., Buchel C., Braus D.F., Herpertz S.C. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol. Psychiatry 2007, 62:1187-1190.
10. Domes G., Heinrichs M., Michel A., Berger C., Herpertz S.C. Oxytocin improves mind-reading in humans. Biol. Psychiatry 2007, 61:731-733.
11. Domes G., Lischke A., Berger C., Grossmann A., Hauenstein K., Heinrichs M., Herpertz S.C. Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology 2010, 35:83-93.
12. Dumont G.J., Sweep F.C., van der Steen R., Hermsen R., Donders A.R., Touw D.J., van Gerven J.M., Buitelaar J.K., Verkes R.J. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc. Neurosci. 2009, 4:359-366.
13. Feldman R., Gordon I., Zagoory-Sharon O. Maternal and paternal plasma, salivary, and urinary oxytocin and parent - infant synchrony: considering stress and affiliation components of human bonding. Dev. Sci. 2011, 14:752-761.
14. Fischman M.W., Foltin R.W. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br. J. Addict. 1991, 86:1563-1570.
15. Gossen A., Hahn A., Westphal L., Prinz S., Schultz R.T., Grunder G., Spreckelmeyer K.N. Oxytocin plasma concentrations after single intranasal oxytocin administration - a study in healthy men. Neuropeptides 2012, 46:211-215.
16. Gray P.B., Parkin J.C., Samms-Vaughan M.E. Hormonal correlates of human paternal interactions: a hospital-based investigation in urban Jamaica. Horm. Behav. 2007, 52:499-507.
17. Han D.D., Gu H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 2006, 6:6.
18. Harris D.S., Baggott M., Mendelson J.H., Mendelson J.E., Jones R.T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl.) 2002, 162:396-405.
19. Hysek C.M., Domes G., Liechti M.E. MDMA enhances mind reading of positive emotions and impairs mind reading of negative emotions. Psychopharmacology (Berl.) 2012, 222:293-302.
20. Hysek C.M., Liechti M.E. Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. Psychopharmacology (Berl.) 2012, 224:363-376.
21. Hysek C.M., Simmler L.D., Nicola V.G., Vischer N., Donzelli M., Krahenbuhl S., Grouzmann E., Huwyler J., Hoener M.C., Liechti M.E. Duloxetine inhibits effects of MDMA (ecstasy) in vitro and in humans in a randomized placebo-controlled laboratory study. PLOS ONE 2012, 7:e36476.
22. Hysek C.M., Schmid Y., Simmler L.D., Domes G., Heinrichs M., Eisenegger C., Preller K.H., Quednow B.B., Liechti M.E. MDMA enhances emotional empathy and prosocial behavior. Soc. Cogn. Affect Neurosci. 2013, (Epub ahead of print). 10.1093/scan/nst161.
23. Justice A.J., De Wit H. Acute effects of d-amphetamine during the early and late follicular phases of the menstrual cycle in women. Pharmacol. Biochem. Behav. 2000, 66:509-515.
24. Kelly B.C., Parsons J.T., Wells B.E. Prevalence and predictors of club drug use among club-going young adults in New York city. J. Urban Health 2006, 83:884-895.
25. Kirkpatrick M.G., Gunderson E.W., Perez A.Y., Haney M., Foltin R.W., Hart C.L. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl.) 2012, 219:109-122.
26. Kirkpatrick M.G., Lee R., Wardle M.C., Jacob S., de Wit H. Effects of MDMA and intranasal oxytocin on social and emotional processing. Neuropsychopharmacology 2014, (Epub ahead of print). 10.1038/npp.2014.12.
27. Kosfeld M., Heinrichs M., Zak P.J., Fischbacher U., Fehr E. Oxytocin increases trust in humans. Nature 2005, 435:673-676.
28. Lee R., Garcia F., van de Kar L.D., Hauger R.D., Coccaro E.F. Plasma oxytocin in response to pharmaco-challenge to d-fenfluramine and placebo in healthy men. Psychiatry Res. 2003, 118:129-136.
29. Lim M.M., Young L.J. Neuropeptidergic regulation of affiliative behavior and social bonding in animals. Horm. Behav. 2006, 50:506-517.
30. MacDonald E., Dadds M.R., Brennan J.L., Williams K., Levy F., Cauchi A.J. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 2011, 36:1114-1126.
31. Marsh A.A., Yu H.H., Pine D.S., Blair R.J. Oxytocin improves specific recognition of positive facial expressions. Psychopharmacology (Berl.) 2010, 209:225-232.
32. Mens W.B., Witter A., Van Wimersma Greidanus T.B. Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): half-times of disappearance of these neuropeptides from CSF. Brain Res. 1983, 262:143-149.
33. Ramos L., Hicks C., Kevin R., Caminer A., Narlawar R., Kassiou M., et al. Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor. Neuropsychopharmacology 2013, 38:2249-2259.
34. Rodgers J., Buchanan T., Pearson C., Parrott A.C., Ling J., Hefferman T.M., Scholey A.B. Differential experiences of the psychobiological sequelae of ecstasy use: quantitative and qualitative data from an internet study. J. Psychopharmacol. 2006, 20:437-446.
35. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., Partilla J.S. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001, 39:32-41.
36. Sala M., Braida D., Lentini D., Busnelli M., Bulgheroni E., Capurro V., et al. Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol. Psychiatry 2011, 69:875-882.
37. Seltzer L.J., Ziegler T.E. Non-invasive measurement of small peptides in the common marmoset (Callithrix jacchus): a radiolabeled clearance study and endogenous excretion under varying social conditions. Horm. Behav. 2007, 51:436-442.
38. Seltzer L.J., Ziegler T.E., Pollak S.D. Social vocalizations can release oxytocin in humans. Proc. Biol. Sci. 2010, 277:2661-2666.
39. Shahrestani S., Kemp A.H., Guastella A.J. The impact of a single administration of intranasal oxytocin on the recognition of basic emotions in humans: a meta-analysis. Neuropsychopharmacology 2013, 38:1929-1936.
40. Snowdon C.T., Pieper B.A., Boe C.Y., Cronin K.A., Kurian A.V., Ziegler T.E. Variation in oxytocin is related to variation in affiliative behavior in monogamous, pairbonded tamarins. Horm. Behav. 2010, 58:614-618.
41. Striepens N., Kendrick K.M., Hanking V., Landgraf R., Wüllner U., Maier W., Hurlemann R. Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci. Rep. 2013, 3:3440. 10.1038/srep03440.
42. Sumnall H.R., Cole J.C., Jerome L. The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. J. Psychopharmacol. 2006, 20:670-682.
43. Tallarida R.J., Murray R.B. Manual of Pharmacologic Calculations 1981, Springer, Heidelberg, Germany.
44. Tancer M., Johanson C.E. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend. 2003, 72:33-44.
45. Thompson M.R., Callaghan P.D., Hunt G.E., Cornish J.L., McGregor I.S. A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (ecstasy). Neuroscience 2007, 146:509-514.
46. Verrico C.D., Miller G.M., Madras B.K. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl.) 2007, 189:489-503.
47. White T.L., Justice A.J., de Wit H. Differential subjective effects of d-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol. Biochem. Behav. 2002, 73:729-741.
48. Wismer-Fries A.B., Ziegler T.E., Kurian J.R., Jacoris S., Pollak S.D. Early experience in humans is associated with changes in neuropeptides critical for regulating social behavior. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17237-17240.
49. Zak P.J., Stanton A.A., Ahmadi S. Oxytocin increases generosity in humans. PLoS ONE 2007, 2:e1128.